Review anchor
D(4) dopamine receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
D(4) dopamine receptor
CHEMBL219
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats D(4) dopamine receptor as ChEMBL target CHEMBL219, mapped to UniProt P21917. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL219
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21917
D(4) dopamine receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why D(4) dopamine receptor matters
D(4) dopamine receptor is reviewed as D(4) dopamine receptor (UniProt P21917); D(4) dopamine receptor shows approved-linked disease relevance led by psychosis. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 77 approved drugs, 5116 compounds, and 829 assays, with lead potency reaching pChEMBL 10.7.
Protein context
D(4) dopamine receptor
D(4) dopamine receptor Sequence length is 419 aa.
Review this target as D(4) dopamine receptor, mapped to UniProt P21917. Sequence length is 419 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P21917
Protein
Disease context
psychosis
D(4) dopamine receptor shows approved-linked disease relevance led by psychosis. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include CLOTHIAPINE.
Start review with psychosis because it currently carries approved-linked support. Linked drugs include CLOTHIAPINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 77 approved drugs, 5116 compounds, and 829 assays for this target. The dominant activity type is KI. CHEMBL156599 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL156599 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
77 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why D(4) dopamine receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P21917, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why psychosis is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
5116
Total Compounds
829
Total Assays
77
Approved Drugs
IC50: 1336.0, KI: 4815.0, EC50: 544.0, KD: 17.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL156599
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL156845
|
10.6 | Ki | — |
|
|
No preferred name
CHEMBL2420894
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL2106650
|
10.5 | Ki | Clinical |
|
|
No preferred name
CHEMBL157322
|
10.4 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LUMATEPERONE TOSYLATE
CHEMBL3233142
|
2019 |
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
CARIPRAZINE
CHEMBL2028019
|
2015 |
|
|
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
|
2015 |
|
|
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
|
2011 |
|
|
ASENAPINE
CHEMBL3187365
|
2009 |
|
|
PALIPERIDONE
CHEMBL1621
|
2006 |
|
|
ROTIGOTINE
CHEMBL1303
|
2006 |
|
|
TEGASEROD MALEATE
CHEMBL1516474
|
2002 |
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
ZIPRASIDONE
CHEMBL708
|
2001 |
|
|
FROVATRIPTAN SUCCINATE
CHEMBL2138684
|
2001 |
|
|
APOMORPHINE
CHEMBL53
|
2001 |
|
|
ROPINIROLE
CHEMBL589
|
1997 |
|
|
PRAMIPEXOLE
CHEMBL301265
|
1997 |
|
|
PRAMIPEXOLE DIHYDROCHLORIDE
CHEMBL3182733
|
1997 |
|
|
SERTINDOLE
CHEMBL12713
|
1996 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
|
1994 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
EBASTINE
CHEMBL305660
|
1990 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
HALOPERIDOL DECANOATE
CHEMBL1200986
|
1986 |
|
|
AMOXAPINE
CHEMBL1113
|
1980 |
|
|
BROMOCRIPTINE
CHEMBL493
|
1978 |
|
|
LOXAPINE
CHEMBL831
|
1975 |
|
|
DOPAMINE HYDROCHLORIDE
CHEMBL1557
|
1974 |
|
|
DOPAMINE
CHEMBL59
|
1974 |
|
|
FENTANYL
CHEMBL596
|
1968 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
THIORIDAZINE
CHEMBL479
|
1962 |
|
|
FLUPHENAZINE
CHEMBL726
|
1959 |
|
|
CHLORPROMAZINE
CHEMBL71
|
1957 |
|
|
PROCHLORPERAZINE
CHEMBL728
|
1956 |
|
|
DIHYDROERGOTAMINE MESYLATE
CHEMBL1200517
|
1946 |
Source Header